Chronic Lymphocytic Leukemia Laboratory

Combining translational, epidemiological and clinical research to develop individually tailored supportive care and CLL specific treatment.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The clinical course of CLL is highly heterogeneous. During the last decade, the treatment options for CLL has developed from single and combination chemotherapy to immune-chemotherapy and targeted agents, thereby significantly improving the outcome for patients. A more comprehensive approach to immune complications, treatment outcome, and disease outcome among patients with CLL is warranted. 

By capture of paraclinical, clinical and demographic data along with genetic and functional characterization of primary CLL cells in our laboratory, we assemble multidimensional data on patients with CLL through the PERSIMUNE platform. With this unique three-pronged setup (translational research, clinical trials and registry based "real world evidence"), we explore patterns predictive of treatment outcome, infectious complications and disease outcome upon specific treatment. 

By development of machine learning based algorithms in collaboration with DTU Compute, we aim for individually tailored CLL specific treatment and supportive care in CLL. By developing investigator-initiated, inter-group studies in collaboration between the Nordic, Hovon and German CLL study groups, we assure assessment of novel combination treatments for CLL and form a basis for testing individually tailored treatment in future clinical trials

Key results

With the B-cell receptor pathway as the core, our group has been part of a paradigm shift for treatment of CLL with novel targeted therapies developed also for patients with the most dismal outcome due to TP53 aberrations. With the parallel development of translational and experimental studies based on our own unique CLL biobank, CLL epidemiology studies based on the comprehensive Danish National CLL database, and CLL clinical inter-group trials, we have created a unique position for development of not only prognostic algorithms but also tailored novel treatment regimens, which can be prospectively validated via investigator-initiated clinical trials.

People

Carsten Utoft Niemann, MD, PhD, Principal Investigator, Head of CLL Laboratory, Chair of Nordic CLL Study Group

Mail: carsten.utoft.niemann@regionh.dk

Christian H. Geisler, Prof Emeritus, MD

Clinical scientists

Caspar da Cunha-Bang, MD, PhD 

Fie Juhl Vojdeman, MD, PhD: currently Dept of Biochemistry, Bispebjerg Hospital

Rudi Agius Post. Doc. 

Christian Brieghel, MD, PhD: Herlev Hospital

Ph.D. candidates

Rebecka Svanberg, MD 

Emelie Hamotal Curovic Rotbain, MD

Mehdi Parvis, upcoming  PhD student

Tereza Faitová, upcoming PhD student

 

Former lab members

Rebecca XMS Valentin, MD

Michael Asger Andersen, MD

Kathrine Aarup

Noomi Vainer

 

Laboratory staff

Lone Bredo Pedersen, Scientific laboratory technician

Trine Enevoldsen, laboratory technician, in collaboration with the clinical trial unit

Jane Hinrichsen, laboratory technician, in collaboration with the clinical trial unit

Betina Gall, laboratory technician, in collaboration with the clinical trial unit

Louise Le Dous, laboratory staff

Marianne Blirup Jensen, laboratory staff

 

Research Associate:

Mette Højmose Thrane

 

Collaborators

  • Finn Cilius Nielsen, Prof, MD, PhD: Center for Genomic Medicine, Righospitalet.

  • Jens Lundgren, Prof, MD, PhD, PERSIMUNE: Department of Infection Medicine, Rigshospitalet.

  • Henrik Hjalgrim, MD, PhD, DMSc, SSI: Statens Serum Institut.

  • Matthew S. Davids, MD, PhD: Dana-Farber Cancer Institute, MA, USA

  • Adrian Wiestner, MD, PhD, NHLBI: National Institutes of Health, MD, USA

  • Arnon P Kater, Prof, MD, PhD, AMC: HOVON study group, Amsterdam, the Netherlands.

  • Michael Hallek, Prof, MD, PhD: University of Cologne, German CLL study group, Cologne, Germany

  • Ole Winther, Prof, MSc: DTU, DTU Compute, Cognitive Science.

  • Anders Österborg Prof, MD: Nordic CLL study group: http://www.nordic-cll.org/

  • Richard Rosenquist Brandell Prof, MD: Nordic CLL study group: http://www.nordic-cll.org/

  • Sigrid Skånland, PhD: Department of Cancer Immunology, Oslo University Hospital

Clinical Trials

  • Chronic lymphocytic leukemia:
  • PreVent-ACaLL (recruiting), founding member, sponsor
  • Assure (recruiting)
  • CLL17 (planned), founding member
  • HOVON158, Next Step trial (planned)
  • Vision HO141 trial (completed), founding member
  • GAIA CLL13 trial (completed), founding member
  • CLL3011 GLOW (completed), founding member 
  • CLL14 (completed)
  • HOVON68 (completed), founding member
  • MURANO (completed)
  • PROLONG (completed), founding member

Mantle Cell Lymphoma:

  • Triangle (recruiting), responsible for laboratory analyses
  • Philemon (completed), responsible for laboratory analyses
  • Valeria (recruiting), responsible for laboratory analyses
  • Vision (recruiting), responsible for laboratory analyses

Videos

Selected publications

Rotbain E, Niemann CU, Rostgaard K, da Cunha-Bang C, Hjalgrim H, Frederiksen H Mapping comorbidity in chronic lymphocytic leukemia: Impact of individual comorbidities on treatment, mortality, and causes of death, Leukemia, in press

Egholm GJ, Andersen MA, Andersen CL, Frederiksen H, Bjerrum OW, Niemann CU: Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival, BritishJHaematology, in press

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U, on behalf of the ESMO Guidelines Committee: Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2020, DOI:https://doi.org/10.1016/j.annonc.2020.09.019

Levin M-D, Kater AP, Mattsson M, Kersting S, Ranti J, Tran HTT, Nasserinejad K, Niemann CU: Protocol description of the HOVON 141 / VIsion Trial: a prospective, multicenter, randomized phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, BMJopen, 2020;10:e039168. doi:10.1136/bmjopen-2020-039168 

Andersen MA, Valentin R, Dissing Sjö L, Borgwardt L, Schmiegelow K, Andersen MK, Marvig RL, Yde CW, Niemann CU: Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma, Acta Oncol, 2020, doi: 10.1080/0284186X.2020.1821913. Online ahead of print. 

Niemann CU, Levin M, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CMH, Dobber JA, Poulsen CB, Frederiksen H, Janssens AM, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M,  Tran HTT,  Nasserinejad K, Kater AP: Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia, Blood, 2020, doi: 10.1182/blood.2020008608.

Niemann CU: Cost-effectiveness targeting CLL, Blood, 2020, doi: 10.1182/blood.2020006949

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Du K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner C, Kreuzer K, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K: Fixed-duration venetoclax-obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia: follow-up of efficacy and safety results from the multicentre, open-label, randomised, phase 3 CLL14 trial, Lancet Onc, in press.

Aarup K, Rotbain EC, Enggaard L, Pedersen RS, Bergmann OJ, Thomsen RH, Frederiksen M, Frederiksen H, Nielsen T, Christiansen I, Andersen MA*, Niemann CU* (* co senior-authors): Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib, Eur J Hem, 2020, doi: 10.1111/ejh.13499

Helleberg M, Niemann CU, Moestrup K, Kirk O, Lebech A, Clifford L, Lundgren J: Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy, Journal of Infectious Diseases, 2020, doi: 10.1093/infdis/jiaa446

Andersen MA, Rostgaard K, Niemann CU, Hjalgrim H: Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study. Leukemia 2020, doi.org/10.1038/s41375-020-0980-0

Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P: COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 doi: 10.1038/s41375-020-0959-x

Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, van der Klift M, van der Spek E, Illmer T, Schöttker B, Fischer K, Wendtner CM, Tausch E, Stilgenbauer S, Niemann CU, Gregor M, Kater AP, Hallek M and Eichhorst B: COVID-19 among fit patients with CLL treated with venetoclax-based combinations, Leukemia, 2020 doi: 10.1038/s41375-020-0941-7

Andersen MA, Niemann CU, Rostgaard K, Dalby T, Sørrig R, Weinberger DM, Hjalgrim H and Harboe ZB: Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16 year Cohort Study, Clinical Infectious Disease, 2020, doi: 10.1093/cid/ciaa090

Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, Bentzen HHN, Frederiksen H, Christiansen I, Nielsen LH, Enggaard L, Helleberg M, Clausen MR, Frederiksen M, Pedersen RS, Niemann CU*, Andersen MA* (* co senior-authors): Richter's Transformation in Patients with Chronic Lymphatic Leukemia: A Nationwide Epidemiological Study; Leukemia & Lymphoma, 2020 doi: 10.1080/10428194.2020.1719092

Agius R, Brieghel B, Andersen MA, Pearson AT , Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR, Larsen J, Niemann CU: Identification of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia at High Risk of Infection or Treatment using an Ensemble Machine Learning Algorithm – Selection of Patients for Enrollment in a Clinical Trial to Improve Immune Dysfunction, Nature Communications, 2020 DOI: 10.1038/s41467-019-14225-8

Brieghel B, da Cunha-Bang C, Yde CW, Schmidt AY, Kinalis S, Nadeu F, Andersen MA, Jacobsen LO, Andersen MK, Pedersen LB, Delgado J, Baumann T, Mattsson M, Mansouri L, Rosenquist R, Campo E,. Nielsen FC, Niemann CU: Number of Signaling Pathways Altered by Driver Mutations as a Prognostic Biomarker in Chronic Lymphocytic Leukemia, Clin Cancer Res. 2020 Jan 9. pii: clincanres.4158.2018. doi: 10.1158/1078-0432.CCR-18-4158. [Epub ahead of print]

Kater AP, Levi, M-D, Niemann CU: To the Editor: Ibrutinib and venetoclax for first-line treatment of CLL", NEJM 2019, DOI: 10.1056/NEJMc1908754

Rotbain EC, Frederiksen H, Hjalgrim H, Rostgaard K, Jakupsdottir Egholm G, Zahedi B, Poulsen CB, Enggaard L, da Cunha-Bang C, Niemann CU: IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. Haematologica. 2019 Oct 3. DOI: 10.3324/haematol.2019.220194

de Weerdt I, Hofland T, Boer R, Dobber J, Dubois J, Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin M-D, Eldering E, Tonino SH and Kater AP: Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment, Blood Advances 2019, DOI 10.1182/bloodadvances.2019000360

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

Hleuhel MH, Ben-Dali Y, Da Cunha-Bang C, Brieghel C, Clasen-Linde E, Niemann CU, Andersen MA: Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study. BMJ Open. 2019 Mar 3;9(3):e023566. doi: 10.1136/bmjopen-2018-023566

Andersen MA, Moser CE, Lundgren J, Niemann CU: Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study, Leukemia 2019, doi: 10.1038/s41375-018-0316-5

Bidrag (CLL og lymfoproliferative sygdomme) til Kap. 34: Blodsygdomme i Medicinsk Kompendium (19. udgave) red. af Jesper Hastrup, Hendrik Vilstrup og Ove Schaffalitzky, 2019, ISBN 978-87-628-1752-4

Brieghel C, Kinalis S ,Yde CW, Schmidt AY, Jønson L ,Andersen MA, da Cunha-Bang C, Pedersen LB, Geisler CH Nielsen FC, Niemann CU: Deep Targeted sequencing of TP53 in chronic lymphocytic leukemia. Hematologica 2018 doi:10.3324/haematol.2018.195818

Da Cunha-Bang C, Niemann CU: Targeting Bruton's tyrosine kinase across B cell malignancies, Drugs 2018, doi: 10.1007/s40265-018-1003-6

Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A: Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study. Blood. 2018 Feb 26. pii: blood-2017-12-820910. doi: 10.1182/blood-2017-12-820910.

Andersen MA, Eriksen CT, Brieghel C, Ciccler JL, da Cunha-Bang C, Helleberg M, Niemann CU: Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study, Haematologica, 2018 doi:10.3324/haematol.2017.182006

Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A: Ibrutinib-Lenalidomide-Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.  The Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial, Lancet Haem, 2018,doi: 10.1016/S2352-3026(18)30018-8.

Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S: ERIC Recommendations for TP53 Mutation Analysis in Chronic Lymphocytic Leukemia – Update on Methodological Approaches and Results Interpretation, Leukemia, 2018, , doi:10.1038/s41375-017-0007-7

Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, Chiorazzi N, Izumi R, Ulrich R, Lannutti BJ, Wiestner A, Herman SEM: Combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model. Clin Cancer Res. 2017 doi: 10.1158/1078-0432.CCR-17-0650.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.:Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2017 Oct 10. doi: 10.1002/cyto.b.21595.

Vojdeman FJ,  Herman SEM, Kirkby N, Wiestner A, van t'Veer MB, Tjønnfjord GE, Itälä- Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH and Niemann CU: Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia, Leuk Lymphoma. 2017 doi.org/10.1080/10428194.2017.1285027

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann CU, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K: TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017 doi: 10.1182/blood-2017-04-779736.

Niemann CU and Christiansen I: Kronisk Lymfoproliferative Sygdomme, kapitel i Hæmatologi i klinisk praksis (Overgaard U and Birgens H ed.), Munksgaard januar 2017

Niemann CU and Christiansen I: Kronisk Lymfoproliferative Sygdomme, kapitel i Hæmatologi i klinisk praksis (Overgaard U and Birgens H ed.), Munksgaard januar 2017

von-Tresckow J, Bahlo J, Niemann CU, Kater AP, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Stilgenbauer S, van Oers R, Geisler CG, Hellek M, Eichhorst B: The GAIA (CLL13) trial – an international, randomized, four-arm study for first line treatment of physically fit CLL patients without del17p or TP53 mutation, Integr Cancer Sci Therap, 2017 doi: 10.15761/ICST.1000252 Volume 4(5): 1-2

Niemann CU and Christiansen I: Kronisk Lymfoproliferative Sygdomme, kapitel i Hæmatologi i klinisk praksis (Overgaard U and Birgens H ed.), Munksgaard 2016.

Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, Harrington B, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Urlich R, Johnson AJ, Lannutti BJ, Wiestner A, and Woyach JA: The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia, Clin Cancer Res. 2016 nov, DOI: 10.1158/1078-0432.CCR-16-0463

da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H and Niemann CU: Improved survival for Patients diagnosed with Chronic Lymphocytic Leukemia in the era of Chemo-immunotherapy - a Danish Population Based Study of 10455 patients, Blood Cancer J. 2016 Nov 11;6(11):e499. doi: 10.1038/bcj.2016.105

da Cunha-Bang C, Geisler CH, Enggaard L, Poulsen CB, de Nully Brown P, Frederiksen H, Bergman O, Pulczynski E, Pedersen R, Nielsen L, Christiansen I, Niemann CU: The Danish National CLL Registry, Clinical Epidemiology, 2016 Oct 25;8:561-565

da Cunha-Bang C, Christiansen I, Niemann CU: The International prognostic Index for patients with chronic lymphocytic leukemia (CLL-IPI) applied in a population-based cohort. Blood. 2016 Oct 27;128(17):2181-2183

Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen, 20Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R: Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016 Aug;101(8):959-67. Doi: 10.3324/haematol.2016.141812

Andersen MA, Andersen MK, Vojdeman FJ, de Nully Brown P, Geisler CH, Bjerrum OW, Niemann CU: Hypogammaglobulinemia in Newly Diagnosed Chronic Lymphocytic Leukemia is a predictor of early death. Leuk Lymphoma. 2016 Jul;57(7):1592-9. doi: 10.3109/10428194.2016.1142082

Niemann CU, Herman SEMH, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, Stetler-Stevenson M, Yuan C, Calvo KR, Braylan RC, Valdez J, Lee YS, Wong DH, Jones J, Sun CCL, Marti GE, Farooqui MZ, Wiestner A: Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study, Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965

Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D, Stetler-Stevenson M, Marti GE, Calvo KR, Yuan CM, Valdez J, Soto S, Farooqui MZH, Herman SEM, Wiestner A: Inter¬actions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combi¬nation therapy, Clin Cancer Res. 2016 Jan 1;22(1):86-95. doi: 10.1158/1078-0432.CCR-15-1304. 

Lipsky AH, Farooqui MZH, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SEM, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner A: Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib, Haematologica. 2015 Dec;100(12):1571-8. doi: 10.3324/haematol.2015.126672

Farooqui MZH, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SEM, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A: Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9

Herman SEM*, Niemann CU*, Farooqui M*, Jones J, Mustafa RZ, Lipsky A, Saba N, Martyr S, Soto S, Valdez J, Gyamfi JA, Maric I, Calvo KR, Pedersen LB, Geisler CH, Liu D, Marti GE, Aue G, Wiestner A: Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014 Nov;28(11):2188-96. doi: 10.1038/leu.2014.122. *shared 1st authors

Niemann CU, Geisler CH: Målrettet behandling af lymfoproliferativ sygdom: Kinasehæmmere og Bcl-2 hæmmere, Ugeskr Læger 2014;176:V66229

Niemann CU: Målrettet behandling af kronisk lymfatisk leukæmi, Statusartikel, Ugeskrift for Læger, 2014, April, Ugeskr Læger 2014;176:V11130682

Niemann CU, Polliack A, Hutchings M: Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where. Leuk Lymphoma. 2014 Feb;55(2):233-4

Niemann CU, Wiestner A: B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol. 2013 Dec;23(6):410-21

Niemann CU, Jones J, Wiestner A: Towards targeted therapy of Chronic Lymphocytic Leukemia, book chapter in: Advances in Chronic Lymphocytic Leukemia, in the series: Advances in Experimental Medicine and Biology, 2013;792: 259-91


Responsible editor